Deep-brain recordings show Mounjaro and Zepbound briefly shut down craving circuits linked to food noise in a patient with severe obesity
Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quiete
This paper reports on deep-brain recordings conducted in a patient with severe obesity who was treated with Mounjaro and Zepbound. The study aimed to investigate how these medications affect neural activity associated with food cravings within the central nervous system.
The researchers utilized deep-brain recording techniques to monitor brain activity while the patient received treatment. This approach allowed for direct observation of neural circuits involved in regulating food-related behaviors and reward processing.
Findings indicated that both Mounjaro and Zepbound temporarily suppressed craving circuits connected to food noise signals. The medication appeared to quiet the nucleus accumbens, which serves as a critical hub for reward processing in the brain. Consequently, the patient's obsessive thoughts regarding food diminished during the treatment period.
It is important to note that these results are preliminary and derived from a single case study. The findings should not be interpreted as clinical recommendations or medical advice. Further research is required to establish broader efficacy and safety profiles before any potential applications in metabolic research contexts.